Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
Authors:
- Manon Penco-CampilloMPManon Penco-Campillo
- Clément MolinaCMClément Molina
- Patricia PirisPPPatricia Piris
- Nouha SoufiNSNouha Soufi
- Manon CarréMCManon Carré
- Marina Pagnuzzi-BoncompagniMPMarina Pagnuzzi-Boncompagni
- Vincent PiccoVPVincent Picco
- Maeva DufiesMDMaeva Dufies
- Cyril RoncoCRCyril Ronco
- Rachid BenhidaRachid Benhida
- Sonia MartialSMSonia Martial
- Gilles PagèsGilles Pagès
Open Access
Abstract
Medulloblastoma (MB) is the most common and aggressive paediatric brain tumour. Although the cure rate can be as high as 70%, current treatments (surgery, radio- and chemotherapy) excessively affect the patients’ quality of life. Relapses cannot be controlled by conventional or targeted treatments and are usually fatal. The strong heterogeneity of the disease (four subgroups and several subtypes) is related to innate or acquired resistance to reference treatments. Therefore, more efficient and less-toxic therapies are needed. Here, we demonstrated the efficacy of a novel inhibitor (C29) of CXCR1/2 receptors for ELR+CXCL cytokines for the treatment of childhood MB. The correlation between ELR+CXCL/CXCR1/2 expression and patient survival was determined using the R2: Genomics Analysis and Visualization platform. In vitro efficacy of C29 was evaluated by its ability to inhibit proliferation, migration, invasion, and pseudo-vessel formation of MB cell lines sensitive or resistant to radiotherapy. The growth of experimental MB obtained by MB spheroids on organotypic mouse cerebellar slices was also assayed. ELR+CXCL/CXCR1/2 levels correlated with shorter survival. C29 inhibited proliferation, clone formation, CXCL8/CXCR1/2-dependent migration, invasion, and pseudo-vessel formation by sensitive and radioresistant MB cells. C29 reduced experimental growth of MB in the ex vivo organotypic mouse model and crossed the blood–brain barrier. Targeting CXCR1/2 represents a promising therapeutic strategy for the treatment of paediatric MB in first-line treatment or after relapse following conventional therapy.Keywords
Funding Information
- Fondation BMS (874708)
- Rueil-Malmaison (FRANCE) (874708)
- H2020 TheraLymph (874708)
This publication has 63 references indexed in Scilit:
- Modulation of CXCL‐8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasisCancer Medicine, 2012
- Subgroup-specific structural variation across 1,000 medulloblastoma genomesNature, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growthCell Death & Differentiation, 2010
- CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenograftsJournal of Clinical Investigation, 2010
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling PathwaysMolecular Cancer Research, 2010
- CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer CellsJournal of Oncology, 2010
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instabilityCarcinogenesis, 2009
- Dicer, Drosha, and Outcomes in Patients with Ovarian CancerNew England Journal of Medicine, 2008